Evidence map›Paper›PMID 35659601›Full record

ArticleBMC infectious diseases2022

SEB genotyping: SmartAmp-Eprimer binary code genotyping for complex, highly variable targets applied to HBV.

Diane Delobel, Yutaka Furutani, Sumiko Nagoshi, Akihito Tsubota, Akio Miyasaka, Koichi Watashi, Takaji Wakita, Tomokazu Matsuura, Kengo Usui

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Diane DelobelGenetic Diagnosis Technology Unit, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan.
Yutaka FurutaniLiver Cancer Prevention Research Unit, RIKEN Cluster for Pioneering Research, Wako, Saitama, 351-0198, Japan.
Sumiko NagoshiDepartment of Gastroenterology and Hepatology Saitama Medical Center, Saitama Medical University, Saitama, 350-8550, Japan.
Akihito TsubotaCore Research Facilities, Research Center for Medical Science, The Jikei University School of Medicine Minato-Ku, Tokyo, 105-8461, Japan.
Akio MiyasakaDivision of Hepatology, Department of Internal Medicine, Iwate Medical University, School of Medicine, Shiwa-gun, Iwate, 028-3695, Japan.
Koichi WatashiDepartment of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.
Takaji WakitaNational Institute of Infectious Diseases, Tokyo, Japan.
Tomokazu MatsuuraDepartment of Laboratory Medicine, The Jikei University School of Medicine, Minato-ku, Tokyo, 105-8461, Japan.
Kengo UsuiGenetic Diagnosis Technology Unit, RIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan. kengo.usui@riken.jp.
Jikei University School of Medicine · JPRIKEN Center for Integrative Medical Sciences · JPIwate Medical University · JPKyoto University · JPNational Institute of Infectious Diseases · JPPioneer (Japan) · JPSaitama Medical University · JP

Funding

Japan Agency for Medical Research and Development JP21fk0310112Ministry of Education, Culture, Sports, Science and Technology RIKEN Center for Integrative Medical Sciences
6 · The paper itself

Abstract

backgroundSmartAmp-Eprimer Binary code (SEB) Genotyping is a novel isothermal amplification method for rapid genotyping of any variable target of interest.

methodsAfter in silico alignment of a large number of sequences and computational analysis to determine the smallest number of regions to be targeted by SEB Genotyping, SmartAmp primer sets were designed to obtain a binary code of On/Off fluorescence signals, each code corresponding to a unique genotype.

resultsApplied to HBV, we selected 4 targets for which fluorescence amplification signals produce a specific binary code unique to each of the 8 main genotypes (A-H) found in patients worldwide.

conclusionsWe present here the proof of concept of a new genotyping method specifically designed for complex and highly variable targets. Applied here to HBV, SEB Genotyping can be adapted to any other pathogen or disease carrying multiple known mutations. Using simple preparation steps, SEB Genotyping provides accurate results quickly and will enable physicians to choose the best adapted treatment for each of their patients.

Indexed as

DNA, ViralHepatitis B virusGenotypeHumansDNA, ViralGenotypingHepatitis B virusHigh mutation rateInfectious diseasesIsothermal amplification

Identifiers

PMID35659601
PMCPMC9164387
OpenAlexW4281715383

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.